Skip to main content
PLUVICTO Now Approved Pre-chemotherapy. For your patients with PSMA+ mCRPC, strive for Pluvictory. A chance to live longer without progression. That's a victory.

PLUVICTO: The first and only PSMA-targeted RLT now approved after only 1 ARPI1

PLUVICTO targets PSMA, a biomarker overexpressed in more than 80% of men with prostate cancer1,3,4

In the PSMAfore trial after only 1 ARPI,

PLUVICTO more than doubled median rPFS vs a change in ARPI2

  • Updated exploratory analysis: Median rPFS was 11.6 months with PLUVICTO vs 5.6 months with a change in ARPI (HR=0.49 [95% CI, 0.39-0.61])2,†

PLUVICTO has a favorable safety profile and proven tolerability2 

  • Grade ≥3 AE rates were lower in the PLUVICTO group with a longer median duration of exposure2

  • 6% permanent discontinuation rate due to an AE; 4% had a dose modification due to an AE; 12% had a dose interruption due to an AE1,2

  • Most common ARs (≥20%) in PSMA+ mCRPC after 1 ARPI: dry mouth, fatigue, nausea, constipation, decreased appetite, and arthralgia1

PLUVICTO can be delivered within 5 days of order placement, so your patients can begin treatment as soon as possible5

Choose PLUVICTO: Proven in 2 large phase 3 trials and ~20K patients treated from launch to date1,2,6,7,§

AE, adverse event; AR, adverse reaction; ARPI, androgen receptor pathway inhibitor; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive; RLT, radioligand therapy; rPFS, radiographic progression-free survival.
*For patients considered appropriate to delay taxane-based chemotherapy.1
Exploratory rPFS analysis was performed with a median follow-up period of 24 months vs the primary analysis at 7 months. This analysis was not controlled for Type-I error.2
Exceptions may apply for syringe form and select geographic locations.5
§Based on data from February 2025.
References: 1. Pluvicto. Prescribing information. Novartis Pharmaceuticals Corp. 2. Morris MJ, Castellano D, Herrmann K, et al; PSMAfore Investigators. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227-1239. doi:10.1016/S0140-6736(24)01653-2 3. Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. doi:10.3389/fonc.2018.00623 4. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines. J Nucl Med. 2020;61(3):405-411. doi:10.2967/jnumed.119.230318 5. Data on file. Order Lead Time. Novartis Pharmaceuticals Corp; 2025. 6. Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. doi:10.1056/NEJMoa2107322 7. Data on file. PLUVICTO NPS Numbers. Novartis Pharmaceuticals Corp; 2025.